AI Eye Podcast: AI Stocks in the News: (OTCPINK: GTCH) (NYSE: JNPR)

AI Eye Podcast: AI Stocks in the News: (OTCPINK: GTCH) (NYSE: JNPR)

Episode Transcript

(00:00):
Welcome to today's edition of the AIIwatching stock news, deal Tracker and advancements
in Artificial Intelligence. Hello everyone,this is Sam Mowers here. Welcome to
the latest episode of the AII podcastfor stock News. Today, GBT Technologies

(00:21):
has received a notice of publication forits Sigma continuation patent and Juniper's Missed AI
is being deployed at Oxford. Thenwe're going to take a look at some
projections for the global market for AIbased clinical trial solutions for patient matching.
Just before we get into the show, though, a quick reminder that if

(00:42):
you enjoy this podcast to please feelfree to share it or leave us a
review, And as always, Irecommend checking out some of the other podcasts
on investor ideas dot com. Thisincludes the Cannabis Podcast, the Clean Tech
and Climate Change Podcast, along withmany other all of which will bring you
up to speed on the latest stocknews and trends in their respective spaces.

(01:07):
Right so, GBT Technologies, Inc. Which trades on the OTC Pink under
the ticker symbol GTCH, has receiveda Notice of publication for its continuation patent
application for Automatic correction of integrated circuitsElectrical connectivity mismatches. This one is codenamed
Sigma. This continuation application aims toenhance and strengthen particularly Sigma's AI technology,

(01:36):
focusing on intelligent systems and methods toautomate integrated circuits electrical connectivity errors correction.
According to the press release, thetechnology's goal is to eliminate the manual,
tedious and time consuming correction task,improving the microchips, overall silicone area,
its performance and electrical characteristics and strengththinning. The AI technology will enable vast

(02:01):
data processing, efficient correction, handling, complex area computations, optimization and utilization
in a reasonable time. Next upfor today, Juniper Networks, Inc.
Which trades on the NYSE under theticker symbol j NPR, has announced that

(02:23):
numerous departments and colleges of the Universityof Oxford have deployed Juniper's cloud delivered wireless
access solution driven by Missed AI toprovide a modern digital experience to students,
faculty, staff and guests. RobertJones, that's Oxford's managed network services manager

(02:44):
and of IT services rather said quote, AI driven networking from Juniper has delivered
on the requirement to improve network visibilityand control for Oxford's units subscribing to the
managed wireless service with the tools toresolve issues quickly. The actionable insight provided

(03:04):
by missed AI is phenomenal, enablingus to have better visibility into end user
experiences. End quote. We'll pivotaway from stock news at this point and
take a look now at a reportpublished by Polaris Market Research, finding that
the global market for AI based clinicaltrial solutions for patient matching is projected to

(03:27):
grow from a two hundred and fiftythree point one three million USD in twenty
twenty two to two point eight sevenbillion dollars in twenty thirty two, registering
a compound annual growth rate of twentynine point two percent in the forecast period
running from twenty twenty three to thirtytwo. The following excerpt from the report's

(03:49):
description outlines the major factors contributing tothe market's growth. Quote. The market
is poised for significant growth due tothe advancements AI and machine learning technologies that
have paved the way for sophisticated algorithmsand tools to analyze large data sets to
identify suitable patients for clinical trials byleveraging factors like demographics, medical history,

(04:15):
genetic profiles and lifestyle information. AIbased solutions can match patients with specific trial
criteria accurately and efficiently. The increasingdemand for personalized medicine is driving the growth
of the market. Personalized medicine aimsto provide tailored treatments based on individual characteristics.
Clinical trials play a crucial role indeveloping such therapies. AI based patient

(04:41):
matching solutions can swiftly identify patients withthe traits or biomarkers required for a particular
trial, aligning with the demand forpersonalized medicine and accelerating the development of targeted
treatments and quote. And that's itfor today's ai I. If you would
like to be a guest your sponsorfor this podcast, contact Investorideas dot com.

(05:04):
Investor Ideas reminds all listeners to readour disclaimers and disclosures on the investor
Ideas dot com website, and thispodcast is not an endorsement to buy products
or services or securities. Investors arereminded all investment involves risk and possible loss
of investment. To hear more investorIdeas dot com podcasts, please visit investor

(05:26):
Ideas dot com, Slash audio andremind you. You can also hear our
podcasts on Apple Podcasts, Audible,Spotify, tune In, Stitcherdspreeker dot com,
iHeartRadio, and most audio platforms available. To learn more about GBT Technologies,
Inc. Please visitgbtti dot com orvisit the Investor Ideas dot Com profile

(05:46):
page at Investor Ideas dot com,slashco, slash goph and for disclosure purposes,
GBT Technologies is a PR news andsocial media featured company on Investor Ideas stock com